Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia

Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia

HMG-CoA reductase inhibitors (statins) are effective lipid-altering drugs for the treatment of dyslipidemia in patients with type 2 diabetes mellitus. We conducted a randomized, double-blind, placebo-controlled, crossover design trial to determine the effects of simvastatin, 80 mg/day, on plasma lip...

Full description

Bibliographic Details
Main Authors: Merle Myerson, Colleen Ngai, Jeffrey Jones, Steve Holleran, Rajasekhar Ramakrishnan, Lars Berglund, Henry N. Ginsberg
Format: Article
Language:English
Published: Elsevier 2005-12-01
Series:Journal of Lipid Research
Subjects:
very low density lipoproteins
low density lipoproteins
triglycerides
3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors
statins
diabetes mellitus
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520328625

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520328625

Similar Items